ImmunityBio Stock Soars 100% in 2026 on Blockbuster Drug Sales
ImmunityBio shares surge with 10-day winning streak as ANKTIVA cancer drug revenue jumps 700% to $113M. Saudi approval and analyst targets signal more upside ahead.
/ 9 items
#IBRX↓
ANKTIVA Shows Promise in Lung Cancer Treatment
ImmunityBio's (IBRX) ANKTIVA demonstrates improved immune response and survival in non-small cell lung cancer patients when combined with checkpoint inhibitors.
ImmunityBio Shares Jump on European Bladder Cancer Treatment Recommendation
ImmunityBio stock climbed 8.5% after European regulators recommended approval for Anktiva, a bladder cancer treatment that helped over 70% of patients in clinical trials.